Tecentriq wins EU approval for treating advanced lung and bladder cancer
Related Biotechnology, Pharmaceutical and Healthcare News
The European Commission has granted a marketing authorization for Tecentriq (atezolizumab) as a monotherapy…
Original Article: Tecentriq wins EU approval for treating advanced lung and bladder cancer
NEXT ARTICLE
More From BioPortfolio on "Tecentriq wins EU approval for treating advanced lung and bladder cancer"